Resistance to daunorubicin in acute myeloid leukemia is associated with mutations in the TET2 gene
10.19405/j.cnki.issn1000-1492.2018.02.016
- VernacularTitle:AML对柔红霉素的耐药性与TET2基因突变的相关性
- Author:
Liu YANG
1
;
Jian GE
;
Ruixiang XIA
Author Information
1. 安徽医科大学第一附属医院血液内科
- Keywords:
acute myeloid leukemia;
TET2;
daunorubicin;
drug resistance
- From:
Acta Universitatis Medicinalis Anhui
2018;53(2):246-250
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of leukemia-related genes on drug resistance in patients with acute myeloid leukemia (AML). Methods 74 patients with newly diagnosed AML were selected and 54 leukemia-associated genes of all patients were sequenced by second-generation gene sequencing. The gene with the highest mutation rate was further analyzed in association with resistance to several common chemotherapy medicines in in vitro drug sensitivity assays. In addition, in vitro drug resistance data were compared with the clinical data of patients. Results The TET2 gene was the most frequent mutation among 74 patients with newly diagnosed AML, with 11 positive patients. Among these 11 TET2 positive patients, 9 (81. 82％ ) were resistant to daunorubicin, while only 4 (6. 35％ ) out of 63 TET2 negative patients were resistant to daunorubicin. Besides, there was no significant difference between in vitro resistance rate to daunorubicin and the clinical data of patients. Conclusion TET2 gene mutation is associated with resistance to daunorubicin in AML patients, which may become an important indicator of the therapeutic efficacy of DA regimen.
